{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:44:36Z","timestamp":1785890676463,"version":"3.56.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204781"],"award-info":[{"award-number":["82204781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents","doi-asserted-by":"publisher","award":["ZWB-2020\\u201318"],"award-info":[{"award-number":["ZWB-2020\\u201318"]}],"id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ23H290006"],"award-info":[{"award-number":["LQ23H290006"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Reviews in Mutation Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.mrrev.2025.108578","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:54:03Z","timestamp":1765180443000},"page":"108578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Mechanisms, treatment strategies and predictive biomarkers of drug resistance in acute myeloid leukemia"],"prefix":"10.1016","volume":"797","author":[{"given":"Jianjian","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of acute myeloid leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"issue":"11","key":"10.1016\/j.mrrev.2025.108578_bib2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s11864-022-01021-8","article-title":"Pathogenic mechanisms in acute myeloid leukemia","volume":"23","author":"Chakraborty","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.mrrev.2025.108578_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-024-01604-8","article-title":"AML in the elderly - when less may be more","author":"Winer","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.mrrev.2025.108578_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.896426","article-title":"Drug resistance mechanisms of acute myeloid leukemia stem cells","volume":"12","author":"Niu","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108578_bib6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib7","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","article-title":"Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia","volume":"15","author":"Wegmann","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044140","article-title":"Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia","volume":"24","author":"Labbozzetta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.mrrev.2025.108578_bib9","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2016-04-708750","article-title":"Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML","volume":"128","author":"Dany","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mrrev.2025.108578_bib10","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ijc.33908","article-title":"Microenvironment and drug resistance in acute myeloid leukemia: do we know enough?","volume":"150","author":"Ganesan","year":"2022","journal-title":"Int J. Cancer"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11899-017-0378-x","article-title":"Predicting chemotherapy resistance in AML","volume":"12","author":"Yeung","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41375-020-0762-8","article-title":"Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing","volume":"35","author":"Arindrarto","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.mrrev.2025.108578_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114807","article-title":"The non-coding competing endogenous RNAs in acute myeloid leukemia: biological and clinical implications","volume":"163","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-021-01395-7","article-title":"CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia","volume":"20","author":"Liu","year":"2021","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.2019001282","article-title":"PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) acute myeloid leukemia","volume":"134","author":"He","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mrrev.2025.108578_bib17","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1111\/febs.15209","article-title":"Deciphering the molecular mechanism of FLT3 resistance mutations","volume":"287","author":"Georgoulia","year":"2020","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108578_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"issue":"375","key":"10.1016\/j.mrrev.2025.108578_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"7712","key":"10.1016\/j.mrrev.2025.108578_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.mrrev.2025.108578_bib21","doi-asserted-by":"crossref","first-page":"18989","DOI":"10.1039\/D4CP01571A","article-title":"Trans vs. cis: a computational study of enasidenib resistance due to IDH2 mutations","volume":"26","author":"Lindahl","year":"2024","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.mrrev.2025.108578_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215603","article-title":"Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies","volume":"533","author":"Yao","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108578_bib24","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.mrrev.2025.108578_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216767","article-title":"TP53 in MDS and AML: Biological and clinical advances","volume":"588","author":"Zhao","year":"2024","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108578_bib26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","article-title":"Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers","volume":"42","author":"Diepstraten","year":"2024","journal-title":"Cancer Cell"},{"issue":"1-2","key":"10.1016\/j.mrrev.2025.108578_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.drup.2012.02.001","article-title":"Drug resistance: still a daunting challenge to the successful treatment of AML","volume":"15","author":"Shaffer","year":"2012","journal-title":"Drug Resist. Updat"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1194\/jlr.M091876","article-title":"Jr., Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-\u03baB-dependent P-glycoprotein upregulation","volume":"60","author":"Tan","year":"2019","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/16078454.2019.1666219","article-title":"Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia","volume":"24","author":"Hu","year":"2019","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2013.04.006","article-title":"Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K\/Akt pathway in adult acute leukemia","volume":"336","author":"Huang","year":"2013","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108578_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/jhg.2015.105","article-title":"Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML","volume":"60","author":"Hyo Kim","year":"2015","journal-title":"J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib32","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1111\/jcmm.14298","article-title":"Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment","volume":"23","author":"Su","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib33","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","article-title":"Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications","volume":"18","author":"Long","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"issue":"20","key":"10.1016\/j.mrrev.2025.108578_bib34","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/bloodadvances.2020001742","article-title":"Delineation of target expression profiles in CD34+\/CD38- and CD34+\/CD38+ stem and progenitor cells in AML and CML","volume":"4","author":"Herrmann","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib36","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14728222.2022.2083957","article-title":"Acute myeloid leukemia: therapeutic targeting of stem cells","volume":"26","author":"Pabon","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib38","doi-asserted-by":"crossref","DOI":"10.4314\/ajtcam.v8i1.60483","article-title":"Extraction, isolation and characterization of bioactive compounds from plants\u2019 extracts","volume":"8","author":"Sasidharan","year":"2011","journal-title":"Afr. J. Tradit. Complement. Altern. Med."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108578_bib39","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4149\/neo_2022_211004N1408","article-title":"Endothelial lipase promotes acute myeloid leukemia progression through metabolic reprogramming","volume":"69","author":"Shang","year":"2022","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib41","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s12967-023-04579-5","article-title":"Spatiotemporal evolution of AML immune microenvironment remodeling and RNF149-driven drug resistance through single-cell multidimensional analysis","volume":"21","author":"Wu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mrrev.2025.108578_bib42","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","author":"Lasry","year":"2023","journal-title":"Nat Cancer 4(1"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108578_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153157","article-title":"LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation","volume":"132","author":"Moore","year":"2022","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41420-024-01924-5","article-title":"Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia","volume":"10","author":"Spertini","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.mrrev.2025.108578_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653030","article-title":"Study on the immune escape mechanism of acute myeloid leukemia with DNMT3A mutation","volume":"12","author":"Que","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.mrrev.2025.108578_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib47","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mrrev.2025.108578_bib48","doi-asserted-by":"crossref","first-page":"eAO0171","DOI":"10.31744\/einstein_journal\/2023AO0171","article-title":"AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells","volume":"21","author":"Gama","year":"2023","journal-title":"Einstein (Sao Paulo)"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10555-022-10069-9","article-title":"Mesenchymal stromal cell senescence in haematological malignancies","volume":"42","author":"Plakhova","year":"2023","journal-title":"Cancer Metastas.. Rev."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108578_bib50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood.2022019537","article-title":"The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment","volume":"142","author":"Fei","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10238-024-01364-6","article-title":"The effect of bone marrow mesenchymal stromal cell exosomes on acute myeloid leukemia\u2019s biological functions: a focus on the potential role of LncRNAs","volume":"24","author":"Jalilivand","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4024887","article-title":"Mesenchymal stem cell-derived exosomal miRNA-222-3p increases Th1\/Th2 ratio and promotes apoptosis of acute myeloid leukemia cells","volume":"2023","author":"Yuan","year":"2023","journal-title":"Anal. Cell. Pathol."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108578_bib53","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2018-04-845420","article-title":"Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment","volume":"133","author":"Abdul-Aziz","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cbin.11246","article-title":"HIF-1\u03b1 forms regulatory loop with YAP to coordinate hypoxia-induced adriamycin resistance in acute myeloid leukemia cells","volume":"44","author":"Zhu","year":"2020","journal-title":"Cell Biol. Int."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108578_bib55","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib56","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.mrrev.2025.108578_bib57","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/0008-5472.CAN-22-1293","article-title":"Targeting STAT5 signaling overcomes resistance to idh inhibitors in acute myeloid leukemia through suppression of stemness","volume":"82","author":"Liu","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib58","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41467-019-12555-1","article-title":"Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia","volume":"10","author":"Hayashi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mrrev.2025.108578_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101286","article-title":"Targeted therapy in acute myeloid leukemia: resistance and overcoming strategy","volume":"83","author":"Song","year":"2025","journal-title":"Drug Resist Updat"},{"issue":"16","key":"10.1016\/j.mrrev.2025.108578_bib60","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","article-title":"Cytarabine and daunorubicin for the treatment of acute myeloid leukemia","volume":"18","author":"Murphy","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108578_bib61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.mrrev.2025.108578_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107638","article-title":"Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy","volume":"148","author":"Li","year":"2025","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108578_bib63","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib64","first-page":"72","article-title":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Shahswar","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib65","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/bjh.17974","article-title":"Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial","volume":"196","author":"Russell","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mrrev.2025.108578_bib67","article-title":"Comparison of HiDAC versus FLAG-IDA in the treatment of relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome","author":"Tang","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/ejh.13406","article-title":"MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia","volume":"105","author":"Marconi","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108578_bib69","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s00277-023-05400-5","article-title":"Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia","volume":"102","author":"Duan","year":"2023","journal-title":"Ann. Hematol."},{"issue":"20","key":"10.1016\/j.mrrev.2025.108578_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206429","article-title":"A Review of FLT3 Kinase Inhibitors in AML","volume":"12","author":"Negotei","year":"2023","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.mrrev.2025.108578_bib71","doi-asserted-by":"crossref","first-page":"1391743","DOI":"10.3389\/fonc.2024.1391743","article-title":"Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience","volume":"14","author":"Diral","year":"2024","journal-title":"Front Oncol."},{"issue":"23","key":"10.1016\/j.mrrev.2025.108578_bib72","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mrrev.2025.108578_bib73","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108578_bib74","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4155\/fmc-2019-0365","article-title":"Recent advances in FLT3 inhibitors for acute myeloid leukemia","volume":"12","author":"Tong","year":"2020","journal-title":"Future Med Chem."},{"issue":"21","key":"10.1016\/j.mrrev.2025.108578_bib75","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.mrrev.2025.108578_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115820","article-title":"Venetoclax in adult acute myeloid leukemia","volume":"168","author":"Hu","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"5","key":"10.1016\/j.mrrev.2025.108578_bib78","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/bjh.18788","article-title":"Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice","volume":"201","author":"Liu","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108578_bib79","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.mrrev.2025.108578_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910658","article-title":"BCL-2 Inhibitor ABT-737 Effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a NRAS\/BCL-2 mouse model of high risk-myelodysplastic syndrome","volume":"22","author":"Gorombei","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2018-11-883454","article-title":"Venetoclax in AML: aiming for \u201cjust right\u201d","volume":"133","author":"Michaelis","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108578_bib82","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2174\/1568009620666200424145622","article-title":"Targeting IDH mutations in AML: wielding the double-edged sword of differentiation","volume":"20","author":"Becker","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"issue":"18","key":"10.1016\/j.mrrev.2025.108578_bib83","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1080\/14656566.2023.2272659","article-title":"Ivosidenib in acute myeloid leukemia","volume":"24","author":"Bruzzese","year":"2023","journal-title":"Expert Opin. Pharm."},{"issue":"13","key":"10.1016\/j.mrrev.2025.108578_bib84","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108578_bib85","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2020.01.015","article-title":"AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells","volume":"15","author":"Lotsberg","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib87","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"de Botton","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib88","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-Mutated Myeloid Malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.mrrev.2025.108578_bib89","article-title":"HMPL-306 in relapsed or refractory IDH1- and\/or IDH2-mutated acute myeloid leukemia: a phase 1 study","author":"Hu","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2643-3230.BCD-24-0171","article-title":"Venetoclax-based combination regimens in acute myeloid leukemia","volume":"6","author":"Goulart","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib91","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mrrev.2025.108578_bib92","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c02332","article-title":"Development of Dual FLT3 and CHK1 PROTACs for the Treatment of AML","author":"Lian","year":"2025","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib93","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/jm201198w","article-title":"VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia","volume":"55","author":"Heidary","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mrrev.2025.108578_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107964","article-title":"Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies","volume":"153","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.mrrev.2025.108578_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107889","article-title":"Synergy and antagonism between azacitidine and FLT3 inhibitors","volume":"169","author":"Yang","year":"2024","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03242-x","article-title":"Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines","volume":"15","author":"Kalkan","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mrrev.2025.108578_bib97","doi-asserted-by":"crossref","first-page":"1271722","DOI":"10.3389\/fonc.2023.1271722","article-title":"CPX-351 in FLT3-mutated acute myeloid leukemia","volume":"13","author":"Andrews","year":"2023","journal-title":"Front Oncol."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108578_bib98","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib99","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41375-022-01786-9","article-title":"Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms","volume":"37","author":"Walti","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"10388","key":"10.1016\/j.mrrev.2025.108578_bib101","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib102","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108578_bib103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.18877","article-title":"Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy","volume":"202","author":"Ge","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.mrrev.2025.108578_bib104","article-title":"TP53 mutations in acute myeloid leukemia: still a daunting challenge?","volume":"10","author":"Molica","year":"2020","journal-title":"Front Oncol."},{"issue":"39","key":"10.1016\/j.mrrev.2025.108578_bib105","doi-asserted-by":"crossref","first-page":"42345","DOI":"10.18632\/oncotarget.5645","article-title":"IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association","volume":"6","author":"Debarri","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108578_bib106","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2021005789","article-title":"Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation","volume":"7","author":"Bill","year":"2023","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108578_bib107","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s12094-022-02781-3","article-title":"Distinct power of bone marrow microRNA signatures and tumor suppressor genes for early detection of acute leukemia","volume":"24","author":"Memari","year":"2022","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/CBM-190211","article-title":"High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia","volume":"27","author":"Fang","year":"2020","journal-title":"Cancer Biomark."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108578_bib109","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/21655979.2019.1652490","article-title":"Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia","volume":"10","author":"Guo","year":"2019","journal-title":"Bioengineered"},{"issue":"17","key":"10.1016\/j.mrrev.2025.108578_bib110","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2012.45.6228","article-title":"Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients","volume":"31","author":"Marcucci","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mrrev.2025.108578_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216880","article-title":"circRNAs as prognostic markers in pediatric acute myeloid leukemia","volume":"591","author":"Sun","year":"2024","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108578_bib112","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7150\/thno.80054","article-title":"Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia","volume":"13","author":"Xia","year":"2023","journal-title":"Theranostics"},{"issue":"516","key":"10.1016\/j.mrrev.2025.108578_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.mrrev.2025.108578_bib114","first-page":"233","article-title":"Lysosome-mediated chemoresistance in acute myeloid leukemia","author":"Cuesta-Casanovas","year":"2022","journal-title":"Cancer Drug Resist 5(1"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108578_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054790","article-title":"Targeting measurable residual disease (MRD) in acute myeloid leukemia (AML): moving beyond prognostication","volume":"24","author":"Tiong","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2022.03.003","article-title":"Association between diminished miRNA expression and the disease status of AML patients: comparing to healthy control","volume":"46","author":"Chen","year":"2023","journal-title":"Biomed. J."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108578_bib117","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/CBM-191164","article-title":"Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia","volume":"28","author":"Lin","year":"2020","journal-title":"Cancer Biomark."}],"container-title":["Mutation Research - Reviews in Mutation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574225000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574225000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:11:50Z","timestamp":1781323910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383574225000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":117,"alternative-id":["S1383574225000493"],"URL":"https:\/\/doi.org\/10.1016\/j.mrrev.2025.108578","relation":{},"ISSN":["1383-5742"],"issn-type":[{"value":"1383-5742","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms, treatment strategies and predictive biomarkers of drug resistance in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Reviews in Mutation Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrrev.2025.108578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108578"}}